CPHI Barcelona is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Future Therapies
Developing the therapies of the future and moving away from a one-size-fits-all approach
Types
Oct 25th - Room 4.3
Oct 25th 11:00 - 11:15 (CET) Room: 4.3, Conference Centre 4
R&D Review – What are the Therapies of the Future?
Speaker: Alok Tayi, Founder, Vibe Bio
Oct 25th 11:15 - 11:35 (CET) Room: 4.3, Conference Centre 4
Personalised medicine offers not only a wealth of opportunities but also challenges, with collaborative efforts required between all stakeholders within the industry. Join us, where we will delve into what can be done to break down the barriers and improve outcomes in personalised medicine.
• Why lack of regulatory harmonization can hinder adoption of personalized medicine approaches
• Assessing Infrastructure and Technical limitations and what is needed to improve personalized outcomes
• Why Healthcare Integration and Digital Health Initiatives can enhance personalized medicine implementation
Speaker: Reserved for Seqens
Oct 25th 11:40 - 12:00 (CET) Room: 4.3, Conference Centre 4
mRNA vaccines helped us through the COVID- 19 pandemic — but they could also help defend against many other infectious diseases. Join Moderna to understand how mRNA can play a key role in future therapies.
• Learnings from the COVID-19 vaccine and translating mRNA technology to other therapy areas
• How nanoparticles are paving the way to improve vaccine efficiency
Moderator: Raman Sehgal, Founder and Host, Molecule to Market Podcast
Speaker: Nicolas Chornet, Senior Vice President International Manufacturing, Moderna
Oct 25th 12:05 - 12:25 (CET) Room: 4.3, Conference Centre 4
Explore future therapies amidst data and time constraints. Unveil insights through advanced forecasting methods, enhancing medical treatment strategies.
• Navigating timely market insights for future therapies
• Managing fluid data gaps in global markets
• Crafting robust insights for generics and innovators in evolving landscapes
Speaker: Sanobar Syed, Associate Director, BeiGene
Oct 25th 12:30 - 12:50 (CET) Room: 4.3, Conference Centre 4
An overview of current microbiome studies and the potential for improving health outcomes by starting with the gut:
• Understanding current challenges in clinical development to help create a strong framework
• Why does Europe need to take account of US-based studies to help create regulatory pathways?
Speaker: Rajiv Khatau, Managing Director, LODAAT, LLC
Oct 25th 12:55 - 13:40 (CET) Room: 4.3, Conference Centre 4
Networked care is scaling up as an effective model of care for rare diseases, with prevention, diagnosis, care, and treatment administered locally, informed by the body of knowledge and expertise from the whole network.
• How a collaborative network can bring about an effective learning process, a key element for success
• Why patient involvement is crucial to improve success in rare disease outcomes
• Assessing current tested and build practices to help improve manufacturing and development quality of drug products
Moderator:
Raman Sehgal, Founder and Host, Molecule to Market Podcast
Panellists:
Rajiv Khatau, Managing Director, LODAAT, LLC
Nicolas Chornet, Senior Vice President International Manufacturing, Moderna
Alok Tayi, Founder, Vibe Bio
Online
1st Nov 10:45 - 11:15 Europa Room, Hall 4.0-Keynote
1st Nov 11:20 - 11:45 Europa Room, Hall 4.0
The next generation enteric capsule enables pharmaceutical companies to develop a targeted delivery solution while simplifying their manufacturing processes. The solution offers: • An acid-protective dosage form with enteric drug release through a patient centric delivery solution; • A simple encapsulation process that allows for fast and stable preparation. This solution is supported by scientific studies, both in-vitro and in-vivo, showing that enteric protection and targeted delivery to the distal intestine are achieved in comparison to marketed references. Backed up also by performance studies, this capsule showcases excellent machineability and mechanical properties, in line with standard immediate release HPMC capsules. It is available commercially in large quantities. Join Dr. Vincent Jannin to learn more on the newly launched enteric solution.
Talk Sponsor
1st Nov 11:50 - 12:15 Europa Room, Hall 4.1
Overview of LNP as an Innovative Approach to Genomic Medicine and Vaccine Development - Insights on Core Technologies for Developing RNA-LNP Genomic Medicines and Vaccines: The Genomic Medicine Toolkit - Best practices of LNP formulation, optimization and manufacturing - Case Study Snapshots: Using the Genomic Medicine Toolkit for the development of Cell Therapies, Gene Therapies, and Vaccines
Talk Sponsor
1st Nov 12:20 - 12:45 Europa Room, Hall 4.0
Latest Development, the Application of EXCiPACT GMPs to Pharmaceutical Auxiliary Materials EXCiPACT is extending its certification scheme to PAMs and is developing a guide for manufacturers and auditors. As these materials may be in intimate contact with a material which will be administered to patients, they should be manufactured in accordance with GMP principles. Typically, PAMs are removed before use in the manufacture of a drug product or function as processing aids in the manufacture of the excipient. Although the manufacturing processes used for PAMs may not be traditional chemical manufacturing processes, applying the risk-based approach in EXCiPACT GMP means this standard can be applied to PAMs. The guide will help manufacturers apply EXCiPACT GMP to the preparation and distribution of PAMs and auditors to assess their compliance for certification purposes.
Talk Sponsor
In person
Copyright © 2023. All rights reserved. Informa Markets, a trading division of Informa PLC.